OrthoPediatrics (NASDAQ:KIDS) Upgraded by Wall Street Zen to “Hold” Rating

OrthoPediatrics (NASDAQ:KIDS) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $23.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, October 29th. Needham & Company LLC reduced their price target on OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. Lake Street Capital dropped their price objective on OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, October 10th. Piper Sandler cut their price objective on shares of OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Finally, Truist Financial set a $18.00 target price on shares of OrthoPediatrics in a research report on Friday, October 10th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, OrthoPediatrics currently has an average rating of “Moderate Buy” and an average price target of $24.00.

OrthoPediatrics Price Performance

Shares of KIDS opened at $18.41 on Friday. The business’s 50-day moving average is $17.49 and its 200-day moving average is $19.66. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.40 and a quick ratio of 3.52. The company has a market capitalization of $461.72 million, a price-to-earnings ratio of -9.44 and a beta of 1.06. OrthoPediatrics has a fifty-two week low of $15.28 and a fifty-two week high of $27.60.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Monday, January 9th. The company reported ($0.15) EPS for the quarter. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.86%. The company had revenue of $25.08 million for the quarter. Equities research analysts expect that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On OrthoPediatrics

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in shares of OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after buying an additional 1,139 shares during the period. Caption Management LLC acquired a new position in OrthoPediatrics during the 3rd quarter worth $54,000. BNP Paribas Financial Markets boosted its holdings in OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,235 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of OrthoPediatrics in the second quarter valued at about $220,000. Finally, PDT Partners LLC bought a new position in shares of OrthoPediatrics in the first quarter worth about $244,000. Institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.